Initiating the Interim Analysis – - REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 - - Company to Host Webcast Call Today at 9:00 am ET NEW YORK, Dec. 10, 2024 ...
Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens - - Overall Response Rate (ORR) of 56% Achieved to ...
SELLAS Life Sciences Group ( (SLS) ) has issued an announcement.
4d
Analyst Jason McCarthy of Maxim Group maintained a Buy rating on SELLAS Life Sciences Group (SLS – Research Report), retaining the price target ...
NEW YORK - SELLAS Life Sciences Group, Inc. (NASDAQ: NASDAQ:SLS), a biopharmaceutical company specializing in cancer therapies with a market capitalization of $80.24 million, has announced ...
"We are highly encouraged by the emerging data, which continue to show the potential of SLS009 to transform outcomes of these heavily pretreated AML patients,” said Angelos Stergiou, MD, ScD h.c., ...
For more information on the study, visit clinicaltrial.gov identifier NCT04588922. About SELLAS Life Sciences Group, Inc. SELLAS is a late-stage clinical biopharmaceutical company focused on the ...
(RTTNews) - SELLAS Life Sciences Group, Inc. (SLS) on Monday announced additional data from the expansion cohorts in the Phase 2 trial of SLS009 in patients with relapsed/refractory acute myeloid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback